Ugur Sahin Sells 20,500 Shares of BioNTech (NASDAQ:BNTX) Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 20,500 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $96.31, for a total value of $1,974,355.00. Following the sale, the chief executive officer directly owned 688,209 shares of the company’s stock, valued at $66,281,408.79. The trade was a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total value of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Stock Up 0.3%

Shares of BioNTech stock opened at $96.73 on Friday. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The company has a market cap of $24.46 billion, a P/E ratio of -12.35 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The firm has a fifty day moving average of $96.98 and a two-hundred day moving average of $95.38.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company’s revenue was down 59.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.60) earnings per share. On average, analysts forecast that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on BNTX shares. BMO Capital Markets downgraded BioNTech from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $128.00 to $105.00 in a research note on Tuesday. Morgan Stanley decreased their price target on BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a report on Monday, June 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. Finally, Citigroup reduced their target price on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and an average target price of $126.00.

Hedge Funds Weigh In On BioNTech

Several hedge funds have recently added to or reduced their stakes in BNTX. Royal Bank of Canada lifted its holdings in shares of BioNTech by 95.9% in the first quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after purchasing an additional 3,514 shares in the last quarter. NewEdge Advisors LLC acquired a new position in shares of BioNTech during the 1st quarter worth approximately $167,000. Russell Investments Group Ltd. raised its position in shares of BioNTech by 368,800.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock worth $1,178,000 after purchasing an additional 11,064 shares during the last quarter. Natixis purchased a new stake in BioNTech in the 2nd quarter valued at approximately $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in BioNTech by 2.9% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company’s stock valued at $52,416,000 after buying an additional 13,788 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.